Health Care Equipment
Case studies in health care equipment.
Abbott and Exact Sciences: How Much Integration, and Where?
Six months after Abbott completed its acquisition of Exact Sciences, the combined company had reported its first full quarter with Exact included in reported results. Abbott's acquisition presentation forecast at least $100 million in annual pretax synergies by 2028 and projected earnings dilution through 2027. Read case
Baxter and Hillrom: integrating without disrupting care
On Monday, 13 December 2021, Baxter International announced that it had completed its acquisition of Hillrom. Baxter had paid $156 in cash for each Hillrom share, for a purchase price of approximately $10.5 billion based on shares outstanding at closing. Read case
Becton Dickinson: Preparing for a Phasix Indication That Has Not Yet Been Proven
Imagine that you advise Becton, Dickinson and Company’s Surgery leadership on October 2, 2026. The question is how much to invest in preparing for possible U.S. prophylactic use of Phasix Mesh while a large clinical trial remains in follow-up. This is a hypothetical resource-allocation decision, not a reported management meeting or an announced BD budget. Read case
Boston Scientific: Resilience, Integration and the Next Dollar
On August 25, Boston Scientific identified a cybersecurity incident that disrupted global operations. Manufacturing, order processing and shipping were limited. The company’s first public notice said the scope and financial impact were then unknown. Read case
CapsoVision — The First AI Commercial Bet
On September 28, CapsoVision announced that the FDA had cleared AI Highlights for use with its CapsoCam Plus capsule endoscopy system. The clearance was granted three days earlier. Read case
Dexcom: Where Should Stelo Begin?
On July 25, 2024, Dexcom reported second-quarter revenue of $1.004 billion, up 15% from a year earlier. U.S. revenue grew 19%. Read case
Edwards Lifesciences — Where to Place the Next Structural Heart Investment?
On July 23, 2026, Edwards Lifesciences reported second-quarter sales of $1.741 billion, up 13.6% on a reported basis and 12.5% in constant currency. TAVR, the company’s largest platform, generated $1.26 billion, up 11.3% reported and 10.5% in constant currency. TMTT, its transcatheter mitral and tricuspid portfolio, generated $195.9 million. Read case
Strategy Case: GE HealthCare — Turning Precision Care into a Portfolio
On February 13, 2025, GE HealthCare reported its 2024 results and filed its annual report. The company described a year of product launches, acquisitions, margin improvement, and continued investment in its “precision care” strategy. It also reported only 1% revenue growth, a 15% decline in its China region, and free cash flow below the prior year. Read case
Hologic: Integrating Sonata into GYN Surgical
Hologic’s acquisition of Gynesonics added Sonata to a portfolio that already included several products used in gynecologic surgery. The acquisition had closed earlier that year. A hypothetical assignment asks you, as a member of GYN Surgical leadership, to recommend how Hologic should organize Sonata’s commercial and clinical-support work over the next 12 months. Read case
IDEXX inVue Dx — How Fast Should the Rollout Grow?
At 6:30 a.m. Eastern on October 31, 2024, IDEXX Laboratories reported nearly 700 pre-orders for its new inVue Dx cellular analyzer and said shipments were expected to begin later in the fourth quarter. An earnings call was scheduled for 8:30 a.m. . Read case
Insulet Corporation — Sequencing Omnipod 5’s Next Releases
Insulet’s Omnipod 5 is a tubeless automated insulin delivery (AID) system that works with compatible continuous glucose monitors (CGMs). Users can select among compatible sensors; availability depends on regulatory clearance, launch timing and local access. Insulet describes its system as combining a pod, controller or compatible smartphone, and CGM. Read case
Intuitive Surgical — Who Gets the First da Vinci 5 Systems?
Intuitive Surgical ended 2023 with a da Vinci installed base of approximately 8,606 systems across hospitals worldwide. Those systems supported approximately 2.286 million procedures during the year, up 22% from 2022. The company placed 1,370 da Vinci systems in 2023: 666 in the United States and 704 outside it. Read case
Medtronic: How Fast Should Hugo Go?
On September 1, Medtronic announced a roughly $700 million investment and strategic partnership with Cornerstone Robotics. The agreement covered staged funding and rights to distribute Cornerstone’s Sentire robotic system in selected markets outside the United States. Medtronic described Sentire as complementary to Hugo, its own robotic-assisted surgery system. Read case
Omnicell: Connecting the Pharmacy—at What Pace?
On December 12, 2024, Omnicell's leadership team was closing out the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in New Orleans. Three days earlier, the company had announced OmniSphere, a cloud-native workflow engine and data platform intended to connect its automation and medication-management products. Read case
ResMed — Where Should the Next Capacity Go?
At the close of business on 26 October 2023, ResMed had just released results for the first quarter of fiscal 2024. Its sleep and respiratory devices and masks remained central to the business. It also operated several software businesses and digital-health tools whose relationships to those products varied considerably. Read case
STERIS: Governing the Mentor manufacturing transition
On May 11, STERIS announced that it would invest approximately $60 million over two years in a new sterility-assurance manufacturing plant in Mentor, Ohio. The plant is intended to consolidate existing U.S. production and was expected to be operational in late calendar 2027. The investment is announced; the operating transition still has to be designed. Read case
Stryker: Who Owns the Customer Relationship?
The second-quarter operating review had left Stryker's leadership with a question that the published numbers could not answer. The company's reported Vascular sales were nearly flat year over year in the quarter, but the U.S. and international lines moved in opposite directions. Inari Medical, acquired in February 2025, now sat within Stryker's Peripheral Vascular business. Read case
Zimmer Biomet: Sequencing ROSA Shoulder
On March 1, 2024, Zimmer Biomet’s strategy team is preparing for the expected U.S. availability of ROSA Shoulder in the second half of 2024. FDA has granted 510(k) clearance. Read case